Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis

Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV... Background Until recently, the role of antiviral prophylaxis in preventing hepatitis B virus (HBV) reactivation during immunosuppressive therapy or chemotherapy in patients with resolved HBV infection was unclear. The aim of the study reported here was to compare the efficacy of antiviral prophylaxis versus that of non-prophylaxis in resolved HBV-infected patients undergoing chemotherapy or immunosuppressive therapy. Methods PubMed, the Cochrane library, and the ClinicalTrials.gov website were searched from inception until December 2017. Studies comparing reactivation in prophylaxis versus non-prophylaxis in patients undergoing immu- nosuppressive therapy or chemotherapy were included. The meta-analysis was performed to calculate the relative risk (RR) and the pooled estimates. Results A meta-analysis was conducted of 13 studies (2 randomized controlled trials [RCTs] and 11 cohort studies). The summary RR for HBV reactivation was 0.47 (95% confidence interval [CI] 0.13–1.69) for antiviral prophylaxis versus non-prophylaxis. Both of the RCTs included in the meta-analysis enrolled patients treated with rituximab. Subgroup analyses showed that the two RCTs ± high-quality cohort studies showed a decreased risk of HBV reacti- vation among the antiviral prophylaxis groups (RCT 1: RR 0.13, 95% CI 0.02–0.70; P = 0.02; RCT 2: 0.28, 95% CI 0.08–0.98; P = 0.05). Subgroup analyses further showed that http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Pharmacology Springer Journals

Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis

Download PDF
9 pages
Read Article

Loading next page...
 
/lp/springer_journal/antiviral-prophylaxis-during-chemotherapy-or-immunosuppressive-drug-c9A0pTjvAo
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Biomedicine; Pharmacology/Toxicology
ISSN
0031-6970
eISSN
1432-1041
DOI
10.1007/s00228-018-2487-4
pmid
29845351
Publisher site
See Article on Publisher Site

Abstract

Background Until recently, the role of antiviral prophylaxis in preventing hepatitis B virus (HBV) reactivation during immunosuppressive therapy or chemotherapy in patients with resolved HBV infection was unclear. The aim of the study reported here was to compare the efficacy of antiviral prophylaxis versus that of non-prophylaxis in resolved HBV-infected patients undergoing chemotherapy or immunosuppressive therapy. Methods PubMed, the Cochrane library, and the ClinicalTrials.gov website were searched from inception until December 2017. Studies comparing reactivation in prophylaxis versus non-prophylaxis in patients undergoing immu- nosuppressive therapy or chemotherapy were included. The meta-analysis was performed to calculate the relative risk (RR) and the pooled estimates. Results A meta-analysis was conducted of 13 studies (2 randomized controlled trials [RCTs] and 11 cohort studies). The summary RR for HBV reactivation was 0.47 (95% confidence interval [CI] 0.13–1.69) for antiviral prophylaxis versus non-prophylaxis. Both of the RCTs included in the meta-analysis enrolled patients treated with rituximab. Subgroup analyses showed that the two RCTs ± high-quality cohort studies showed a decreased risk of HBV reacti- vation among the antiviral prophylaxis groups (RCT 1: RR 0.13, 95% CI 0.02–0.70; P = 0.02; RCT 2: 0.28, 95% CI 0.08–0.98; P = 0.05). Subgroup analyses further showed that

Journal

European Journal of Clinical Pharmacology – Springer Journals

Published: May 29, 2018

References

  • Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis
    Paul, S; Saxena, A; Terrin, N
  • American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy
    Perrillo, RP; Gish, R; Falck-Ytter, YT
  • Hepatitis B virus reactivation associated with anti-neoplastic therapy
    Yeo, W; Chan, HL
  • Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
    Liaw, YF; Kao, JH; Piratvisuth, T
  • Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy
    Loomba, R; Rowley, A; Wesley, R
  • Preventing hepatitis B reactivation due to immunosuppressive drug treatments
    Perrillo, RP; Martin, P; Lok, AS
  • Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
    Sarin, SK; Kumar, M; Lau, GK
  • Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection
    Barone, M; Notarnicola, A; Lopalco, G
  • Kinetic and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy
    Hui, CK; Cheung, WW; Zhang, HY
  • Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab
    Yeo, W; Chan, TC; Leung, NW
  • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
    Liberati, A; Altman, DG; Tetzlaff, J
  • Introduction, comparison and validation of meta-essentials: a free and simple tool for meta-analysis
    Suurmond, R; Rhee, H; Hak, T
  • Bias in meta-analysis detected by a simple, graphical test
    Egger, M; Davey Smith, G; Schneider, M
  • Systematic review: lamivuidine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection
    Kohrt, HE; Ouyang, DL; Keeffe, EB
  • Measuring inconsistency in meta-analyses
    Higgins, JP; Thompson, SG; Deeks, JJ; Altman, DG
  • Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B
    Huang, YH; Hsiao, LT; Hong, YC
  • Randomized controlled trial of prophylactic entecavir in HBsAg-negative/anti-HBC-positive lymphoma patients undergoing rituximab-based chemotherapy: preliminary report
    Huang, Y-H; Hong, Y-C; Hsiao, L-T
  • Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study
    Buti, M; Manzano, ML; Morillas, RM
  • Prevents HBV reactivation with tenofovir in anti-HBC positive patients with hematologic malignancies treated with rituximab. Results final visit 18-months (PREBLIN study)
    Buti, M; Manzano, ML; Morillas, RM
  • Safety of monitoring viral and liver function markers in patients with prior resolved hepatitis B infection after kidney transplantation
    Maekawa, H; Yazawa, M; Koitabashi, K
  • Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection
    Padovan, M; Filippini, M; Tincani, A
  • Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience
    Papadopoulos, N; Deutsch, M; Manolakopoulos, S
  • High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin’s lymphoma
    Cho, Y; Yu, SJ; Cho, EJ
  • Lamivudine prophylaxis and treatment of hepatitis B virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab
    Moses, SE; Lim, ZY; Sudhanva, M
  • The effects of nucleoside analogue prophylactic treatment on HBV activation in HBcAb+ patients undergoing immunosuppressive therapy
    Liu, HL; Zhao, Z; Yang, H
  • Viral outcome in patients with occult HBV infection or HCV-ab positivity treated for lymphoma
    Guarino, M; Picardi, M; Vitello, A
  • Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy
    Koo, YX; Tan, DS; Tan, IB; Tao, M; Chow, WC; Lim, ST
  • Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia lymphoma study group
    Kim, SJ; Hsu, C; Song, YQ
  • Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation
    Yoo, JJ; Cho, EJ; Cho, YY
  • The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy
    Lu, S; Xu, Y; Mu, Q
  • Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study
    Hsu, C; Tsou, HH; Lin, SJ
  • Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study
    Seto, WK; Chan, TS; Hwang, YY
  • Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study
    Seto, WK; Chan, TS; Hwang, YY
  • Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?
    Bisceglie, AM; Lok, AS; Martin, P
  • Hepatitis B virus reactivation during immunosuppressive therapy: appropriate risk stratification
    Seto, WK
  • Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy
    Law, MF; Ho, R; Cheung, CK
  • Safety of corticosteroid treatment in rheumatologic patients with markers of hepatitis B viral infection: pilot evaluation study
    Braun-Moscovici, Y; Braun, M; Saadi, T
  • American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy
    Reddy, KR; Beavers, KL; Hammond, SP; Lim, JK; Falck-Ytter, YT
  • Recent US food and drug administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?
    Bisceglie, AM; Lok, AS; Martin, P; Terrault, N; Perrillo, RP; Hoofnagle, JH
  • Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis
    Lok, AS; McMahon, BJ; Brown, RS
  • Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial
    Huang, H; Li, X; Zhu, J
  • Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis
    Zhang, MY; Zhu, GQ; Zheng, JN
  • Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept
    Germanidis, G; Hytiroglou, P; Zakalka, M; Settas, L